Clinical trials: Elevated Blood Pressure
Glaucoma, Retinal Disease
Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100
This study is a prospective comparative study to gather pilot agreement and precision data in normal subjects, subjects with glaucoma, and subjects with retinal disease.
- Conditions
- Glaucoma, Retinal Disease, Healthy
- Trial name
- OCT (NCT03505567)
- Testing
- KOWA OCT Bi-µ, Optovue iVue 100
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
Hypertension
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to placebo, valsartan and olmesartan in participants with essential hypertension.
- Trial name
- NCT00696436
- Testing
- Azilsartan medoxomil, Valsartan, Olmesartan
- Where
- 131 sites in United States, Argentina and 4 more
- Volunteers
- 1,291 people
- Sponsor
- Takeda
Hypertension
Impact of Ramadan on Achieving Joint National Committee (JNC) 7 Treatment Goals in CV Risk Patients
This is an out-patient based prospective, multi-centre, observational post-marketing surveillance study amongst internists and cardiologists.
- Trial name
- NCT01853839
- Where
- 132 sites in Algeria, Egypt and 3 more
- Volunteers
- 1,674 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Evaluation of Atacand® (Candesartan) in Daily Medical Practice
This open label, non-interventional study is to show the efficacy of antihypertensive treatment with Atacand in hypertensive patients.
- Trial name
- NCT00837720
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Pulmonary Hypertension
Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients Diagnosed With Pulmonary Hypertension (PH)
The study will assess the effect of bosentan on pulmonary vascular resistance and exercise capacity in Sickle Cell Disease (SCD) patients diagnosed with Pulmonary Hypertension.
- Trial name
- ASSET-2 (NCT00313196)
- Testing
- bosentan
- Volunteers
- 12 people
- Sponsor
- Actelion
Hypertension
Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.
This will be an open-label, single-dose, non-randomized, five-period crossover study in healthy volunteers. The duration of the study will last up to eleven weeks from screening to follow-up. PK samples will be taken.
- Trial name
- NCT00549510
- Testing
- COREG CR and lisinopril (FDC)
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Primary Open Angle Glaucoma, Ocular Hypertension
ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects
This single-site, dose-escalation study will evaluate safety and tolerability of increasing concentrations of ATS907 in 12 subjects with Primary Open Angle Glaucoma and/or Ocular Hypertension
- Trial name
- NCT01668524
- Testing
- ATS907
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Altheos, Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
This is a pilot, proof of concept study to evaluate the safety and efficacy of ALZ-1101 dosed once daily for 28 days compared to latanoprost 0.005% ophthalmic solution in patients with elevated intraocular pressure not adequately…
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension, Elevated Intraocular Pressure
- Trial name
- NCT01896180
- Testing
- ALZ-1101, Latanoprost
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Alleanza Pharmaceuticals, Inc.
Pulmonary Arterial Hypertension
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH).
- Trial name
- NCT06137742
- Testing
- PF-07868489
- Where
- 46 sites in United States, Australia and 10 more
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypertension, Metabolic Syndrome
Evaluation of the Integrated Radio Frequency Denervation System for the Treatment of Hypertension
The objective of the study is to evaluate the safety of renal denervation using the iRF System and to understand any potential improvement in hypertension.
- Trial name
- RADAR (NCT04740723)
- Testing
- iRF System Renal Denervation
- Where
- 2 sites in Georgia
- Volunteers
- 30 people
- Sponsor
- Metavention
Prehypertension, Elevated Blood Pressure
Effect of TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure
This clinical study aims to assess the efficacy of TOTUM-854, a mix of 6 plant extracts, consumed twice a day on automated office blood pressure in subjects with moderately elevated blood pressure.
- Conditions
- Prehypertension, Elevated Blood Pressure, Blood Pressure, Metabolic Syndrome
- Trial name
- INSIGHT (NCT05469503)
- Testing
- TOTUM-854
- Where
- 10 sites in Bulgaria, France and 1 more
- Volunteers
- 410 people
- Sponsor
- Valbiotis
Pulmonary Arterial Hypertension
Patient Reported Outcomes in Pulmonary Arterial Hypertension
Develop a brief, new, patient reported outcome instrument that is valid for use in clinical practice and clinical trials.
- Trial name
- PROPAH (NCT01792622)
- Testing
- Interview, Questionnaire
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension
Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension
Study to Evaluate the Efficacy and Safety of Aliskiren Hydrochlorothiazide (HCTZ) vs Ramipril in Obese patients (BMI ≥ 30) with Stage 2 Hypertension
- Trial name
- ATTAIN (NCT00772577)
- Testing
- Aliskiren Hydrochlorothiazide, Ramipril
- Where
- 6 sites in United States
- Volunteers
- 386 people
- Sponsor
- Novartis
Pulmonary Arterial Hypertension
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
This study was an extension to study CQTI571A2102 and was to evaluate the long-term safety, tolerability and efficacy of QTI571 (imatinib) in severe pulmonary arterial hypertension patients.
- Trial name
- NCT01392495
- Testing
- Imatinib
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
Glaucoma
OculusGen-Glaucoma Historical Control Study in Taiwan
The purpose of this study is to determine whether the OculusGen Collagen Matrix are effective and safe to implant as an aid of glaucoma surgery.
- Trial name
- NCT00406822
- Testing
- OculusGen Biodegradable Collagen Matrix Implant
- Where
- Taiwan
- Volunteers
- 48 people
- Sponsor
- Pro Top & Mediking Company Limited
Hypertension
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects
The purpose of this study is to evaluate the pharmacokinetics and safety of Fimasartan and rosuvastatin when coadministered or administered alone as a single dose or as multiple doses to healthy male subjects.
- Trial name
- NCT02704702
- Testing
- Fimasartan, Rosuvastatin, Fimasartan + Rosuvastatin
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Safety Study of RMJH-111b to Treat Essential Hypertension
The purpose of this study was to evaluate the safety of RMJH-111b, including how well it is tolerated, and the effect of RMJH-111b on blood pressure in subjects with hypertension.
- Trial name
- NCT02822222
- Testing
- Magnesium citrate, tribasic anhydrous soft gelatin capsule
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- RMJ Holdings, LLC
Essential Hypertension
Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)
Study objective: 1. To evaluate the antihypertensive efficacy, safety and tolerability of the drug after the oral administration of BR-A-657•K at 20~180mg for 4 weeks to patients with essential hypertension. 2.
- Trial name
- Fimasartan (NCT00937651)
- Testing
- Fimasartan (BR-A-657•K) 20 mg, Fimasartan (BR-A-657•K) 60 mg, Fimasartan (BR-A-657•K) 180 mg
- Volunteers
- 81 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Pulmonary Arterial Hypertension
DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study
The purpose of the DelIVery for PAH clinical study is to evaluate the safety of the Medtronic Model 10642 Implantable Intravascular Catheter when used with the Medtronic SynchroMed® II Implantable Infusion System to deliver…
- Trial name
- DelIVery (NCT01321073)
- Testing
- Model 10642 Implantable Intravascular Catheter
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Hypertension (HTN)
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the…
- Trial name
- NCT07543120
- Testing
- QCZ484
- Where
- 25 sites in United States, Japan and 1 more
- Volunteers
- 323 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.